MA44948A1 - Inhibiteurs de bace 1 - Google Patents

Inhibiteurs de bace 1

Info

Publication number
MA44948A1
MA44948A1 MA44948A MA44948A MA44948A1 MA 44948 A1 MA44948 A1 MA 44948A1 MA 44948 A MA44948 A MA 44948A MA 44948 A MA44948 A MA 44948A MA 44948 A1 MA44948 A1 MA 44948A1
Authority
MA
Morocco
Prior art keywords
bace
inhibitors
present
compounds
alzheimer
Prior art date
Application number
MA44948A
Other languages
English (en)
Inventor
Roland Humm
Thorsten Muser
Hans Hilpert
Christian Schnider
Roger Wermuth
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48050604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA44948A1 publication Critical patent/MA44948A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés de formule (i) ayant une activité inhibitrice de bace1, leur fabrication, des compositions pharmaceutiques les contenant et leur utilisation en tant que substances thérapeutiquement actives. Les composés actifs de la présente invention sont utiles dans le traitement thérapeutique et/ou prophylactique de la maladie d'alzheimer, par exemple.
MA44948A 2013-04-11 2014-04-08 Inhibiteurs de bace 1 MA44948A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13163430 2013-04-11
PCT/EP2014/056985 WO2014166906A1 (fr) 2013-04-11 2014-04-08 Inhibiteurs de bace1

Publications (1)

Publication Number Publication Date
MA44948A1 true MA44948A1 (fr) 2020-06-30

Family

ID=48050604

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44948A MA44948A1 (fr) 2013-04-11 2014-04-08 Inhibiteurs de bace 1
MA38556A MA38556A1 (fr) 2013-04-11 2014-04-08 Inhibiteurs de bace1

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA38556A MA38556A1 (fr) 2013-04-11 2014-04-08 Inhibiteurs de bace1

Country Status (19)

Country Link
US (1) US11447478B2 (fr)
EP (1) EP2984086A1 (fr)
JP (2) JP6574756B2 (fr)
KR (1) KR102247765B1 (fr)
CN (1) CN105431430B (fr)
AU (1) AU2014253275B2 (fr)
BR (1) BR112015019412A8 (fr)
CA (1) CA2900433C (fr)
CL (1) CL2015002897A1 (fr)
EA (1) EA027860B1 (fr)
IL (2) IL240263A0 (fr)
MA (2) MA44948A1 (fr)
MX (1) MX2015014083A (fr)
MY (1) MY174747A (fr)
PE (1) PE20151748A1 (fr)
PH (1) PH12015502365B1 (fr)
SG (1) SG11201508412XA (fr)
UA (1) UA119141C2 (fr)
WO (1) WO2014166906A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
EP2912035A4 (fr) 2012-10-24 2016-06-15 Shionogi & Co Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
WO2014134341A1 (fr) * 2013-03-01 2014-09-04 Amgen Inc. Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants
MX374512B (es) 2013-03-08 2025-03-06 Amgen Inc Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso.
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
CN106795147B (zh) 2014-08-08 2020-09-22 美国安进公司 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
WO2017061534A1 (fr) 2015-10-08 2017-04-13 Shionogi & Co., Ltd. Dérivés de dihydrothiazine
JP2017071603A (ja) * 2015-10-09 2017-04-13 塩野義製薬株式会社 ジヒドロチアジンまたはジヒドロオキサジン誘導体を含有する医薬組成物
EP3423450B1 (fr) * 2016-03-01 2019-11-27 H. Hoffnabb-La Roche Ag Inhibiteurs de bace1
AU2019258575A1 (en) 2018-04-27 2020-10-29 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity
KR102467525B1 (ko) 2020-11-26 2022-11-14 이대근 작업자 중개 장치
JP7605446B2 (ja) 2022-04-28 2024-12-24 第一三共株式会社 ベンゾトリアゾール化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
ES2395583T3 (es) 2007-05-10 2013-02-13 Ge Healthcare Limited IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2
PL2233474T3 (pl) 2008-01-18 2015-12-31 Eisai R&D Man Co Ltd Skondensowana pochodna aminodihydrotiazyny
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
MX2012006491A (es) * 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
MY162413A (en) 2011-01-13 2017-06-15 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8883779B2 (en) * 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
CN103717592A (zh) 2011-06-07 2014-04-09 霍夫曼-拉罗奇有限公司 作为bace1和/或bace2抑制剂的卤代-烷基-1,3噁嗪类
CA2837797A1 (fr) 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag [1,3]oxazines
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
MX354173B (es) 2012-01-26 2018-02-16 Hoffmann La Roche Fluorometil-5,6-dihidro-4h-[1,3]oxazinas.
EP2912035A4 (fr) 2012-10-24 2016-06-15 Shionogi & Co Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
WO2014134341A1 (fr) 2013-03-01 2014-09-04 Amgen Inc. Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants

Also Published As

Publication number Publication date
PH12015502365B1 (en) 2019-04-12
US20160052920A1 (en) 2016-02-25
JP2016515638A (ja) 2016-05-30
PH12015502365A1 (en) 2016-02-22
AU2014253275A1 (en) 2015-07-16
MY174747A (en) 2020-05-13
HK1216533A1 (zh) 2016-11-18
EA027860B1 (ru) 2017-09-29
KR20150142001A (ko) 2015-12-21
NZ710050A (en) 2021-03-26
JP2019031532A (ja) 2019-02-28
KR102247765B1 (ko) 2021-05-06
WO2014166906A1 (fr) 2014-10-16
UA119141C2 (uk) 2019-05-10
BR112015019412A8 (pt) 2019-11-12
BR112015019412A2 (pt) 2017-07-18
MA38556A1 (fr) 2017-09-29
IL240263A0 (en) 2015-09-24
JP6574756B2 (ja) 2019-09-11
US11447478B2 (en) 2022-09-20
AU2014253275B2 (en) 2018-10-18
CN105431430A (zh) 2016-03-23
EA201591541A1 (ru) 2016-02-29
MX2015014083A (es) 2016-07-26
PE20151748A1 (es) 2015-12-02
JP6681451B2 (ja) 2020-04-15
CA2900433C (fr) 2021-06-22
CN105431430B (zh) 2019-05-28
CA2900433A1 (fr) 2014-10-16
EP2984086A1 (fr) 2016-02-17
CL2015002897A1 (es) 2016-06-03
IL265496A (en) 2019-05-30
SG11201508412XA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
MA44948A1 (fr) Inhibiteurs de bace 1
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
BR112017015474A2 (pt) inibidores de bace1
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
BR112016007430A2 (pt) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses